Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068001029> ?p ?o ?g. }
- W2068001029 endingPage "1497" @default.
- W2068001029 startingPage "1479" @default.
- W2068001029 abstract "This review summarizes the current status of intravenous immunoglobulin (IVIg) in the treatment of autoimmune neuromuscular disorders and the possible mechanisms of action of the drug based on work in vivo, in vitro, and in animal models. Supply of idiotypic antibodies, suppression of antibody production, or acceleration of catabolism of immunoglobulin G (IgG) are relevant in explaining the efficacy of IVIg in myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and antibody-mediated neuropathies. Suppression of pathogenic cytokines has putative relevance in inflammatory myopathies and demyelinating neuropathies. Inhibition of complement binding and prevention of membranolytic attack complex (MAC) formation are relevant in dermatomyositis (DM), Guillain-Barré syndrome (GBS), and MG. Modulation of Fc receptors or T-cell function is relevant in chronic inflammatory demyelinating polyneuropathy (CIDP), GBS, and inflammatory myopathies. The clinical efficacy of IVIg, based on controlled clinical trials conducted in patients with GBS, CIDP, multifocal motor neuropathy (MMN), DM, MG, LEMS, paraproteinemic IgM anti-myelin-associated glycoprotein (anti-MAG) demyelinating polyneuropathies, and inclusion body myositis is summarized and practical issues related to each disorder are addressed. The present role of IVIg therapy in other disorders based on small controlled or uncontrolled trials is also summarized. Finally, safety issues, risk factors, adverse reactions, spurious results or serological tests, and practical guidelines associated with the administration of IVIg in the treatment of neuromuscular disorders are presented." @default.
- W2068001029 created "2016-06-24" @default.
- W2068001029 creator A5090062651 @default.
- W2068001029 date "1999-11-01" @default.
- W2068001029 modified "2023-10-16" @default.
- W2068001029 title "Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines" @default.
- W2068001029 cites W1489061768 @default.
- W2068001029 cites W1497904783 @default.
- W2068001029 cites W1513412079 @default.
- W2068001029 cites W1595001782 @default.
- W2068001029 cites W1963948426 @default.
- W2068001029 cites W1964265573 @default.
- W2068001029 cites W1966727106 @default.
- W2068001029 cites W1967530329 @default.
- W2068001029 cites W1968975444 @default.
- W2068001029 cites W1969155592 @default.
- W2068001029 cites W1969703956 @default.
- W2068001029 cites W1970850123 @default.
- W2068001029 cites W1971168120 @default.
- W2068001029 cites W1973248581 @default.
- W2068001029 cites W1975133991 @default.
- W2068001029 cites W1976535033 @default.
- W2068001029 cites W1979105454 @default.
- W2068001029 cites W1979470935 @default.
- W2068001029 cites W1979988008 @default.
- W2068001029 cites W1980310072 @default.
- W2068001029 cites W1983100119 @default.
- W2068001029 cites W1983423133 @default.
- W2068001029 cites W1984098270 @default.
- W2068001029 cites W1984679286 @default.
- W2068001029 cites W1984855350 @default.
- W2068001029 cites W1986800768 @default.
- W2068001029 cites W1991027093 @default.
- W2068001029 cites W1993267543 @default.
- W2068001029 cites W1993694158 @default.
- W2068001029 cites W1993942101 @default.
- W2068001029 cites W1994487332 @default.
- W2068001029 cites W1995723779 @default.
- W2068001029 cites W1996105707 @default.
- W2068001029 cites W1996789173 @default.
- W2068001029 cites W1996838316 @default.
- W2068001029 cites W1997396678 @default.
- W2068001029 cites W2001447887 @default.
- W2068001029 cites W2002779814 @default.
- W2068001029 cites W2003149280 @default.
- W2068001029 cites W2003599894 @default.
- W2068001029 cites W2004520740 @default.
- W2068001029 cites W2006861478 @default.
- W2068001029 cites W2006985788 @default.
- W2068001029 cites W2009297062 @default.
- W2068001029 cites W2010067786 @default.
- W2068001029 cites W2010717729 @default.
- W2068001029 cites W2013153064 @default.
- W2068001029 cites W2013362643 @default.
- W2068001029 cites W2014111498 @default.
- W2068001029 cites W2014267188 @default.
- W2068001029 cites W2016566125 @default.
- W2068001029 cites W2017624564 @default.
- W2068001029 cites W2018386112 @default.
- W2068001029 cites W2019791196 @default.
- W2068001029 cites W2021030324 @default.
- W2068001029 cites W2022258023 @default.
- W2068001029 cites W2023182187 @default.
- W2068001029 cites W2026228148 @default.
- W2068001029 cites W2027502308 @default.
- W2068001029 cites W2031195116 @default.
- W2068001029 cites W2033358000 @default.
- W2068001029 cites W2037569685 @default.
- W2068001029 cites W2038758203 @default.
- W2068001029 cites W2038819343 @default.
- W2068001029 cites W2039072312 @default.
- W2068001029 cites W2041588298 @default.
- W2068001029 cites W2046602350 @default.
- W2068001029 cites W2046966094 @default.
- W2068001029 cites W2047288984 @default.
- W2068001029 cites W2048575240 @default.
- W2068001029 cites W2052934267 @default.
- W2068001029 cites W2056518988 @default.
- W2068001029 cites W2061619965 @default.
- W2068001029 cites W2063797334 @default.
- W2068001029 cites W2063882735 @default.
- W2068001029 cites W2064436710 @default.
- W2068001029 cites W2064480749 @default.
- W2068001029 cites W2071489757 @default.
- W2068001029 cites W2071709617 @default.
- W2068001029 cites W2072254606 @default.
- W2068001029 cites W2073714591 @default.
- W2068001029 cites W2073994360 @default.
- W2068001029 cites W2074318260 @default.
- W2068001029 cites W2076986011 @default.
- W2068001029 cites W2078295357 @default.
- W2068001029 cites W2078425070 @default.
- W2068001029 cites W2081369764 @default.
- W2068001029 cites W2082094294 @default.
- W2068001029 cites W2082190687 @default.
- W2068001029 cites W2085454546 @default.
- W2068001029 cites W2088678446 @default.
- W2068001029 cites W2089502456 @default.